U.S. Semiconductors Stock News

NYSE:ST
NYSE:STElectrical

Is Sensata Technologies Holding (ST) Attractively Priced After Recent Share Price Rebound?

If you are wondering whether Sensata Technologies Holding is offering fair value at its current price, this breakdown is designed to give you a clear, numbers first view of the stock. The share price closed at US$35.21 recently, with returns of 6.6% over the last 7 days, 4.9% over 30 days, 0.9% year to date and 26.0% over the past year. The 3 year and 5 year returns stand at a 16.8% decline and 34.4% decline respectively. These mixed returns over different time frames suggest that investors...
NYSE:VRTS
NYSE:VRTSCapital Markets

How Virtus’ New Silvant Growth Opportunities ETF (VGRO) At Virtus Investment Partners (VRTS) Has Changed Its Investment Story

In late 2025, Virtus Investment Partners expanded its actively managed ETF lineup by launching the Virtus Silvant Growth Opportunities ETF (VGRO), run by Silvant Capital Management and built on bottom-up fundamental research. This fund’s “all-weather” growth approach, combining secular and cyclical growth stocks without a strict style or factor bias, underlines Virtus’ emphasis on differentiated active management within its multi-manager ETF platform. With this new actively managed growth...
NasdaqGM:HELP
NasdaqGM:HELPPharmaceuticals

Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity Program - What's Changed

In late 2025, Cybin Inc. filed for a US$100,000,000 at-the-market follow-on equity offering of its common shares, expanding its potential funding capacity. This kind of incremental capital-raising tool can meaningfully influence how investors weigh Cybin’s financing flexibility against the effects of additional share issuance. With the recent share price declines in mind, we’ll now examine how this sizeable at-the-market equity program shapes Cybin’s investment narrative. The end of...
NYSE:KW
NYSE:KWReal Estate

A Look At Kennedy-Wilson (KW) Valuation After Recent Gains And Conflicting Fair Value Estimates

Why Kennedy-Wilson Holdings is on investors’ radar today Kennedy-Wilson Holdings (KW) has drawn attention after a mixed picture in its latest reported fundamentals, with annual revenue of $550.5 million alongside a net loss of $35.3 million. This has prompted closer scrutiny of its real estate focused model. See our latest analysis for Kennedy-Wilson Holdings. At a share price of $9.64, Kennedy-Wilson’s 90-day share price return of 22.96% contrasts with a 5-year total shareholder return...
NasdaqGM:OMER
NasdaqGM:OMERPharmaceuticals

Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch

Omeros (OMER) drew fresh investor attention after the U.S. Food and Drug Administration approved YARTEMLEA for hematopoietic stem cell transplant associated thrombotic microangiopathy, and the company is preparing a U.S. launch and related reimbursement infrastructure. See our latest analysis for Omeros. The FDA approval appears to be the main backdrop for recent price action, with a 30 day share price return of 50.97% and a 90 day share price return of 268.92%. Meanwhile, the 1 year total...
NasdaqCM:DCTH
NasdaqCM:DCTHMedical Equipment

Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative

Delcath Systems recently reported publication of subgroup analyses from its phase 3 FOCUS study of the HEPZATO KIT for unresectable metastatic uveal melanoma in the Journal of Cancer Research and Clinical Oncology, detailing efficacy and safety outcomes across multiple patient categories. The data highlight that patients with lower tumor burden and low or normal LDH experienced meaningfully longer progression-free and overall survival, with many responses emerging only after several...